8:30 am Chairs Opening Remarks

8:40 am Industry Panel to Address the Most Critical Questions for this Nascent & Emerging Therapeutic

Synopsis

• What is the best neoantigen prediction platform?
• What is the most robust approach to identifying the “right” neoantigen?
• How to best deliver a neoantigen therapy, vaccine or cell therapy?
• What type of vaccine, cell based, virus, RNA, DNA, peptide?
• Which approach is safer and more efficacious?
• Should the focus be on shared neoantigens or private neoantigens?

9:20 am Personalised Neoantigen Immunotherapy – Demonstrating Priming of CD8+ T cell Responses is a Key Step

Synopsis

• Typical solid tumor epithelial cells display class I HLA-presented neoantigens (not class II)
• Consistent priming of strong CD8+ T cell responses to these neoantigens is likely key to effective immunotherapy
• We will show phase one clinical and immunogenicity data from a heterologous prime-boost neoantigen immunotherapy program in
solid tumor patients

9:50 am An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens

Synopsis

• Outline a high-performing machine learning approach, trained on mass spectrometry data, that predicts naturally processed and
presented antigens
• Demonstrate how the predictor is integrated with several immune parameters, such HLA binding, in a deep learning layer to predict
bona fide neoantigens
• Illustrate it’s application to significantly improve the identification of neoantigen targets for personalised cancer immunotherapy

10:20 am Speed Networking

Synopsis

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working to advance cell therapies. Benchmark against the industry leaders and establish meaningful business relationships to pursue for the rest of the conference and beyond

Morning Refreshments

PREDICTION & IDENTIFICATION

11.20 Using AI To Accelerate Immunotherapy In Cancer

  • Leveraging AI driven prediction tools and identifying challenges in using AI
    technology to drive neoantigen clinical therapy
  • Uncovering the right data with them right quantity and the right quality to train your algorithms to predict immunogenicity
  • Pushing for fairness in technology comparisons: Assessing advantages and disadvantages across current methodologies for assay technologies
  • Harnessing PIONEER in developing neoantigen based therapeutics

Jens Kringelum, Director, Genomic Immuno-Oncology, Evaxion Biotech

 

11.50 Using Predictive Bioinformatics Algorithms to Determine Neoantigen Peptide Synthesis Difficulty & Subsequent Production Methodology

  • NeoAntigen peptides have been widely reported to be difficult to synthesize due to their hydrophobicity, length, and charge.
  • Leveraging extensive peptide synthesis experience GenScript has developed NeoPreTM, a predictive algorithm which is able to determine peptide synthesis difficulty based on sequence alone.
  • NeoPreTM can then recommend the most efficient approach to successfully synthesizing peptides using one of GenScript’s many synthesis platforms
  • This presentation will highlight how NeoPreTM identifies synthesis difficulty and review successful cases of difficult neoantigen peptide synthesis from several researchers

Raymond Miller, Senior Global Product Manager , Therapeutic Materials
GenScript Biotech Corporation

 

12:20 Driving Antigen Discovery in Cervical Cancer

  • Evaluating how personalised genome or transcriptome sequencing information is essential for neoantigen discovery using LC-MS technology
  • RNAseq allows variant mapping and identification of cryptic antigens
  • Pathogen-driven tumours harbour a range of so far unknown targetable, tumourspecific neoantigen

Nicola Ternette, Head of Immunopeptidomics, University of Oxford

CLINICAL TRANSLATION & MANUFACTURING

12:50 pm Networking Lunch

PREDICTION & IDENTIFICATION

13.50 Discovery of Immunogenic Dark Antigens™ as Targets for Cancer Immunotherapy

  • Ervaxx is pioneering the use of Dark Antigens™ to deliver targeted off-the-shelf cancer immunotherapeutics
  • Dark Antigens™ derive from vast untapped expanses of genetic ‘dark matter’ beyond the normal coding regions of the genome and are selectively activated in cancer
  • We have developed a platform combining transcriptomics and mass
    spectrometry-based immunopeptidomics to identify Dark AntigensTM that are uniquely presented on the surface of cancer cells

Ray Jupp, CSO, Ervaxx LTD

 

14:20 Modelling Neoantigen Prediction

  • Advancing neoantigen prediction
  • Analysing key features
  • Improving neoantigen prediction modelling

Maren Lang, Head of Bioinformatics Research & Development, BioNTech SE

 

14:50 Disease-Specific Immunopeptides for Generation of Soluble TCR Therapies

  • Patient tumour and healthy tissues were enriched for MHC class I peptides and identified by mass spectrometry
  • Population prevalence was used to prioritise tumour-selective immunopeptides as candidate targets
  • Soluble TCRs can be generated against disease-specific immunopeptides for development of targeted therapeutic strategies

Melanie Patterson, Principal Research Scientist II, Abbvie

 

15:20 Prediction and Identification of both HLA Class I & Class II Neo-Epitopes

  • Quality of T cells are more important than quantity of T cells in the TME
  • Tumour mutation burdens do not correlate with PDAC survival, but neoepitope scores, particularly a score system weighing overlapped HLA Class I and Class II epitopes, may correlate better with PDAC survival
  • Both HLA Class I and Class II epitope peptides were eluted from PDAC tumour tissue by using anti-pan HLA Class I antibody and anti-pan HLA Class II antibody, respectively, followed by mass spectrometry analysis. Approximately 20% eluted HLA Class I epitopes and Class II epitopes are overlapped
  • We propose a strategy of developing neoepitope based vaccine or T cell therapy by selecting HLA Class I and HLA Class II overlapped epitopes.

Lei Zheng, Associate Professor, John Hopkins School of Medicine

 

 

CLINICAL TRANSLATION & MANUFACTURING

3:50 pm Afternoon Refreshments & Poster Session

4:30 pm ImmunoID NeXT: A Comprehensive Platform for Improving Neoantigen Prediction, Tumour Escape Mechanism Reporting, TME Assessment, & Tumor Heterogeneity Profiling for Immuno-Oncology

  • Sean Boyle Senior Director, Bioinformatics Applications, Personalis

Synopsis

• Improving neoantigen presentation prediction
• Applying immunopeptidomics and machine learning to more accurately predict neoantigens
• Detecting tumour escape mechanisms
• HLA LOH, antigen presentation machinery, and immunogenomics
• Profiling tumour heterogeneity
• Utilizing cell free DNA in order to more comprehensively identify neoantigens and tumor escape mechanisms

5:00 pm Trailblazing the Development of Off-the Shelf Anti-Cancer Vaccines

Synopsis

• Frameshift neoantigens as targets of cancer immunotherapy
• Shared neopeptides emerging from frameshifts
• Frame neopeptide cocktails as off-the-shelf cancer vaccines

5:30 pm A Personal Antigen Selection Calculator (PASCal) for the Design of Off-The-Shelf, Shared NeoantigenBasedPersonal Vaccines

Synopsis

• Vaccine design approach for two types of vaccines, off-the-shelf and personalized: leveraging Cancer Testis Antigens as nonmutated neoantigens
• Data reveal from phase I/II clinical trial with off the shelf vaccine against mCRC
• Improved selection of Personal Epitopes (PEPIs) that induce cytotoxic T cell responses – exploring our personalised cancer vaccines proof of concept study
• How this technology leads to a shorter needle-to-needle time and a more scalable product

6:00 pm Mastermind Session: Broadening Neoantigen Therapeutic Horizons: Should we Target Unique, Patient-Specific Tumour Mutations or Shared Neoantigens?

Synopsis

• Defining the pros and cons of each therapeutic approach
• Why shared neoantigens are more exciting from a strategy standpoint
• Personlised vaccines targeting neoantigens are designed to prime and amplify neoantigen-specific T cell populations invivo to
augment adoptive antitumor immunity among individuals
• Recognising that off-the-shelf vaccines are more practical then personal vaccines and the potential commercial benefit
• Considerations for time wasted in designing and producing, manufacturing the personlised vaccines
• Realising the economic reality of developing personalised neoantigen based therapies

6:30 pm Chair’s Closing Remarks

6:40 pm End of Day 1 of Neoantigen Summit Europe